A Study of TAS-303 in Female Patients With Stress Urinary Incontinence

NCT02562807 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Stress Urinary Incontinence

Interventions

DRUG: TAS-303 18mg single-dose
DRUG: Placebo 18mg single-dose
DRUG: TAS-303 9mg single-dose
DRUG: Placebo 9mg single-dose

Sponsor

Taiho Pharmaceutical Co., Ltd.